Three-dimensional porous film contact layer with improved wound healing

Information

  • Patent Grant
  • 10258779
  • Patent Number
    10,258,779
  • Date Filed
    Friday, February 17, 2017
    7 years ago
  • Date Issued
    Tuesday, April 16, 2019
    5 years ago
Abstract
A wound dressing has a micro-architecture to produce appropriate strains in cells to promote the healing a wound. The apparatus includes a wound cover for defining a reservoir over a wound in which a negative pressure may be maintained by forming a substantially fluid-tight seal around the wound, a vacuum source in fluid communication with the reservoir and suitable for providing an appropriate negative pressure to the reservoir to stimulate healing of the wound, and a porous structure positioned in contact with the wound for delivering micro-mechanical forces to localized areas of the wound. The porous structure comprises a three-dimensional film material having directional apertures formed therein.
Description
BACKGROUND

1. Technical Field


The present disclosure relates generally to wound healing, and, in particular, relates to methods and devices for the promotion of wound healing through the application of micro-mechanical forces to localized areas of the wound.


2. Background of Related Art


The application of mechanical stresses to a wound has been found to affect healing of the wound. For example, compressive, tensile and shear forces may be applied to a wound to accelerate the natural healing process. Compressive bandages are commonly used for the treatment of venous leg ulcers, or for patients with interstitial edema, which can impair wound healing. Sub-atmospheric pressure applied to wounds such as a pressure sores, ulcers or burns has been found to promote blood flow to the wound area, stimulate the formation of granulation tissue and encourage the migration of healthy tissue over the wound. These techniques tend to apply forces globally or evenly over large areas of the wound or the patient.


It has also been observed that the application of micro-mechanical forces to localized areas of the wound may cause individual cells to react in a manner beneficial for wound healing. Micro-mechanical forces exerted on individual cells can regulate particular cell functions and may even switch on genes that cause cell proliferation. Experimental data suggests that cells subjected from about 10 percent to about 20 percent strain exhibit proliferation rates favorable for wound healing. Accordingly, devices and methods for the application, concentration or regulation of micro-mechanical forces to localized areas of a wound may promote wound healing.


SUMMARY

The present disclosure describes a wound dressing having a micro-architecture to produce appropriate strains in cells to promote the healing of a wound. The apparatus includes a wound cover for defining a reservoir over a wound in which a negative pressure may be maintained by forming a substantially fluid-tight seal around the wound, a vacuum source in fluid communication with the reservoir and suitable for providing an appropriate negative pressure to the reservoir to stimulate healing of the wound, and a porous structure positioned in contact with the wound for delivering micro-mechanical forces to localized areas of the wound. The porous structure comprises a film material having directional apertures formed therein.


The apparatus may include an energy source adapted to deliver energy to the porous structure. The energy source may comprise an ultrasonic horn.


The porous structure may exhibit a male face and an opposite female face, and the porous structure may be positioned such that the male face is in contact with the wound. Alternatively, the porous structure may be positioned such that the female face is in contact with the wound. The directional apertures may be spaced apart by a distance ranging from about 400 microns to about 800 microns, and may be spaced apart by a distance of about 600 microns. The directional apertures may have a diameter ranging from about 50 microns to about 350 microns. The porous structure may exhibit a material thickness ranging from about 25 microns to about 75 microns and a height ranging from about 200 microns to about 300 microns.


According to another aspect of the disclosure, a therapeutic apparatus to promote healing of a wound includes a porous structure in contact with the wound for delivering micro-mechanical forces to localized areas of the wound. The porous structure comprises a film material having directional apertures formed therein. The apparatus also includes an ultrasonic horn adapted to deliver ultrasonic energy to the porous structure.





BRIEF DESCRIPTION OF THE DRAWINGS

The accompanying drawings, which are incorporated in and constitute a part of this specification, illustrate embodiments of the present disclosure and, together with the detailed description of the embodiments given below, serve to explain the principles of the disclosure.



FIG. 1 is a cross sectional view of a therapeutic apparatus in accordance with the present disclosure having a porous structure in contact with the wound;



FIGS. 2A and 2B are respectively a perspective view and an orthographic view of a first portion of the porous structure of FIG. 1; and



FIGS. 2C and 2D are respectively a perspective view and an orthographic view of a second portion of the porous structure of FIG. 1 that is larger than the first portion.





DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS

Referring initially to FIG. 1, an apparatus in accordance with the present disclosure is depicted generally as 10 for use on a wound “w” surrounded by healthy skin “s.” Apparatus 10 defines a negative wound pressure therapy (NWPT) apparatus 10, which may subject the wound “w” to a negative pressure continuously, or in varying intervals depending on the nature and severity of the wound “w”. One suitable NWPT apparatus is disclosed in commonly assigned U.S. patent application Ser. No. 11/516,925, filed Sep. 6, 2006, the entire content of which is hereby incorporated by reference. To facilitate the application of a negative pressure, the apparatus 10 includes a wound dressing 12 positioned relative to the wound “w” to define a reservoir 14 in which a negative pressure appropriate to stimulate healing may be maintained.


Wound dressing 12 includes a contact layer 18 positioned in direct contact with the bed of wound “w.” Contact layer 18 exhibits a three-dimensional structure that is configured to deliver micro-mechanical forces to localized areas of the wound “w” while permitting the negative pressure applied to the reservoir 14 to penetrate into the wound “w.” Contact layer 18 also permits exudates to be drawn from the wound “w.” An appropriate contact layer 18 is discussed in greater detail below with reference to FIGS. 2A through 2D. Three-dimensional formed and apertured films such as those provided by Tredegar Film Products of Richmond, Va., may be suitable for constructing contact layer 18.


Wound filler 20 is positioned in the wound “w” over the contact layer 18 and is intended to allow wound dressing 12 to absorb and capture wound exudates, or to transport wound exudates away from the wound “w” and out of the dressing 12. Wound filler 20 may be cut to a shape that is conformable to the shape of wound “w,” and may be packed up to the level of healthy skin “s,” or alternatively, may overfill the wound “w.” An absorbent material such as gauze, reticulated foam, or alginate fibers may be used for filler 20 to receive or transport any exudate that migrates through contact layer 18. An antimicrobial dressing, commercially available under the trademark KERLIX™ AMD offered by Tyco Healthcare Group LP (d/b/a Covidien), may be suitable for use as filler 20. To prevent adhesion to the wound “w,” the filler 20 may also comprise a material configured such that any stray fibers do not tend to protrude through pores formed in contact layer 18 where they may become engulfed by newly forming granulation tissue. One particular type of material exhibiting this characteristic is formed of continuous filaments comprising either natural or man-made fibers. Continuous filaments include those relatively long strands of a synthetic material such as nylon, rayon, etc., which may offer a smooth continuous outer surface substantially free of the protruding fibrils commonly associated with natural materials such as cotton. The use of continuous filaments of a hydrophobic material such as polyolefin may permit a complete removal of filler 20 when the dressing 12 is changed without re-injuring the wound “w.”


Wound dressing 12 also includes a cover layer 24. Cover layer 24 may be positioned over the wound “w” such that an adhesive on an underside of the cover layer forms a substantially fluid-tight seal with the surrounding skin “s.” Thus, cover layer 24 may act as both a microbial barrier to prevent contaminants from entering the wound “w,” and also a fluid barrier maintaining the integrity of vacuum reservoir 14. Cover layer 24 is preferably formed from a moisture vapor permeable membrane to promote the exchange of oxygen and moisture between the wound “w” and the atmosphere, and is preferably transparent permit a visual assessment of wound conditions without requiring removal of the cover layer 24. A transparent membrane providing a sufficient moisture vapor transmission rate (MVTR) for use as cover layer 24 is sold under the trade name POLYSKIN®II by Tyco Healthcare Group LP (d/b/a Covidien). Alternatively, cover layer 24 may comprise an impermeable membrane or a substantially rigid member.


A vacuum port 30 having a flange 34 may also be included in wound dressing 12 to facilitate connection of the wound dressing 12 to fluid conduit 36. Fluid conduit 36 defines a fluid flow path leading through the apparatus 10. The vacuum port 30 may be configured as a rigid or flexible, low-profile component, and may be adapted to receive a fluid conduit 36 in a releasable and fluid-tight manner. An adhesive on the underside of flange 34 may provide a mechanism for affixing the vacuum port 30 to the dressing 12, or alternatively flange 34 may be positioned within reservoir 14 (not shown) such that an adhesive on an upper side of the flange 34 affixes the vacuum port 30. However it is affixed to the dressing, a hollow interior of the vacuum port 30 provides fluid communication between the fluid conduit 36 and the reservoir 14. Vacuum port 30 may be provided as a pre-affixed component of dressing 12, as a component of fluid conduit 36 or entirely independently. Alternatively, vacuum port 30 may be eliminated from dressing 12 if other provisions are made for providing fluid communication with the fluid conduit 36.


Fluid conduit 36 extends from the vacuum port 30 to provide fluid communication between the reservoir 14 and collection canister 40. Any suitable conduit may be used for fluid conduit 36 including those fabricated from flexible elastomeric or polymeric materials. Fluid conduit 36 may connect to the vacuum port 30, the canister 40, or other apparatus components by conventional air tight means such as friction fit, bayonet coupling, or barbed connectors. The conduit connections may be made permanent, or alternatively a quick-disconnect or other releasable means may be used to provide some adjustment flexibility to the apparatus 10.


Collection canister 40 may comprise any container suitable for containing wound fluids. For example, a rigid bottle may be used as shown or alternatively a flexible polymeric pouch may be appropriate. Collection canister 40 may contain an absorbent material to consolidate or contain the wound drainage or debris. For example, super absorbent polymers (SAP), silica gel, sodium polyacrylate, potassium polyacrylamide or related compounds may be provided within canister 40. At least a portion of canister 40 may be transparent to assist in evaluating the color, quality or quantity of wound exudates. A transparent canister may thus assist in determining the remaining capacity of the canister or when the canister should be replaced.


Leading from collection canister 40 is another section of fluid conduit 36 providing fluid communication with vacuum source 50. Vacuum source 50 generates or otherwise provides a negative pressure to the NWPT apparatus 10. Vacuum source 50 may comprise a peristaltic pump, a diaphragmatic pump or other mechanism that is biocompatible and draws fluids, e.g. atmospheric gasses and wound exudates, from the reservoir 14 appropriate to stimulate healing of the wound “w.” Preferably, the vacuum source 50 is adapted to produce a sub-atmospheric pressure in the reservoir 14 ranging between about 20 mmHg and about 500 mmHg, more preferably, about 75 mmHg to about 125 mmHg, or more preferably, about 40 mmHg to about 80 mmHg.


Apparatus 10 further includes an energy source 60 adapted to supply therapeutic energy to the contact layer 18. The application of energy to the contact layer 18 may concentrate the micro-mechanical stresses that the contact layer 18 applies to wound “w” to further stimulate healing. Energy source 60 comprises an ultrasonic generator that permits various parameters such as output power and frequency to be modulated in order to accommodate particular wound conditions. Energy source 60 is operatively coupled to an appropriate transmitter 62 to transmit energy to the contact layer 18. Here, transmitter 62 comprises an ultrasonic horn, which, in some embodiments, is substantially disconnected from the contact layer 18. The transmitter 62 is thus moveable with respect to wound “w” such that energy may be directed to targeted micro-regions of the wound. For example, the transmitter may be moved around the periphery of wound “w,” which may be more responsive to the application of ultrasonic energy than interior regions of the wound. This arrangement permits energy to be supplied to contact layer 18 through cover layer 24. Alternatively, transmitter 62 of ultrasonic horn 60 and may be placed in contact with cover layer 24 or vacuum port 30 whereby the mechanical energy is transmitted through filler 20 and the exudate to contact layer 18. In some embodiments, transmitter 62 may be directly connected or mounted relative to, or within, cover layer 24 or vacuum port 30 as shown schematically by lines 64, 66, respectively. Ultrasonic horn 60 may be disposable with wound dressing 12. The ultrasonic energy applied will be within therapeutic ranges of frequency and intensity, and will vary with respect to wound type and condition of the wound. A control system 68 containing logic or software may control operation of ultrasonic horn 62 in accordance with predefined treatment modalities as selected by the user.


Ultrasonic energy is a type of mechanical energy that may be effective in transferring motion and mechanical energy directly to the contact layer 18. Alternative types of energy may affect the material properties of the contact layer 18 to cause the contact layer 18 to stretch or deform locally to concentrate the micro-mechanical stresses in the wound “w.” Alternative energy types include light energy, which may be delivered through fiber optics, microwave energy, which may be delivered by an antenna, and magnetic, electrical or heat energy, which may be each be delivered by an appropriately corresponding transmitter.


Referring now to FIGS. 2A through 2D, the contact layer 18 is constructed of an apertured film having a three-dimensional structure. The structure of the film is characterized by a plurality of tapered capillary passages 50, each with a base “B” and an apex “A.” A vertical distance “h” between the apex “A” of a passage 50 and the base of the passage defines a height of the film. The height “h” of the film may be many times greater than a material thickness “t” of the film, and many times smaller than a length “l” or breadth “b” of the film. For example, contact layer 18 may exhibit a material thickness “t” of from about 25 microns to about 75 microns (or approximately 1 to 3 mills), and a height “h” of from about 200 microns to about 300 microns (or approximately 8-12 mills). The film may be customized to have a length “l” and breadth “b” on the order of one to several inches to accommodate a particular wound “w.”


Each tapered passage 50 includes an aperture or opening “O” located at its apex “A,” while the base “B” of each passage 50 is closed. The apex “A” of each passage 50 is oriented on a male face of the film (as shown in each of FIGS. 2A through 2D) where the passages 50 are narrower than at their base “B.” This arrangement may promote a unidirectional flow of wound exudates through the contact layer 18, and thus openings “O” may be described as directional apertures. Exudates may encounter the film as an array of micro-funnels in one direction and an array of collecting basins in the other. For example, orienting contact layer 18 such that a female face of the film (not shown) contacts the wound “w” allows wound exudates to be funneled away from the wound “w” to be received and transported further by filler 20. Unidirectional flow away from the wound “w” may be preferable in some instances to discourage bacteria harbored in the wound exudates from flowing back into the wound bed. Orienting the contact layer 18 with the female face in contact with the wound “w” places the relatively broader bases “B” in contact with the surface of the wound “w.” Micro-mechanical forces may be applied to the wound “w” in these areas of contact as a negative pressure is applied to the reservoir 14.


Alternatively, wound contact layer 18 may be oriented such that the male face contacts the wound “w.” In this orientation, the contact layer 18 may be supported only by the film material in the vicinity of the openings “O” such that a smaller surface area of the wound “w” is in contact with the film material than when compared to the opposite orientation. This arrangement permits micro-mechanical forces to be transferred to localized areas of contact with the wound “w” that may be small enough to appropriately stimulate individual cells.


Various features of the contact layer 18 may be designed to precisely control the healing of the wound “w.” For example, by varying the size, shape and location of the openings “O” over the length “l” and breadth “b” of the contact layer 18, different pressures may be experienced by localized regions of the wound “w” as a particular global pressure is applied to the reservoir 14. The size of openings “O” may be selected for particular wound conditions. In some instances, wound healing may be stimulated by a film having openings “O” with a diameter of from about 50 microns to about 350 microns. Also, a spacing “s” of the openings “O” may be selected to control the application of micro-mechanical forces directed at the wound surface. The spacing “s” between adjacent openings “O” of from about 400 microns to about 800 microns may be appropriate. The shape of the openings “O” may also affect healing. The shape of the openings “O” depicted in FIGS. 2A through 4D is generally round, but oblong or asymmetrical shapes are also contemplated. These shapes may create stress concentrations to further localize the application of micro-mechanical forces to the wound “w.”


Material properties of contact layer 18 such as a film elasticity, material hardness, composition and chemistry may be selected to precisely control aspects of healing. Additionally, agents such as hydrogels and medicaments may be bonded or coated to the contact layer 18 to reduce bioburden in the wound, promote healing and reduce pain associated with changes or removal of the dressing 12. Medicaments include, for example, antimicrobial agents, growth factors, antibiotics, analgesics, and the like. Furthermore, when an analgesic is used, the analgesic could include a mechanism that would allow the release of that agent prior to dressing removal or change.


Although the foregoing disclosure has been described in some detail by way of illustration and example, for purposes of clarity or understanding, it will be obvious that certain changes and modifications may be practiced within the scope of the appended claims.

Claims
  • 1. A method of treating a wound with reduced pressure, the method comprising: applying a three-dimensional film material to a wound, the three-dimensional film material having a plurality of passages defined between a male face and an opposite female face thereof, wherein the three-dimensional film material is positioned such that the male face is in contact with the wound, and wherein each of the passages includes an aperture at an apex oriented on the male face and a base oriented on the female face; andsupplying vacuum from a vacuum source in fluid communication with the three-dimensional film material to apply a negative pressure through the plurality of passages to the wound to stimulate healing of the wound.
  • 2. The method according to claim 1, further comprising forming a reservoir over a wound in which a negative pressure may be maintained by forming a substantially fluid-tight seal around the wound with a wound cover.
  • 3. The method according to claim 2, wherein the reservoir comprises a wound filler.
  • 4. The method according to claim 2, wherein vacuum is supplied through a port in communication with the wound cover.
  • 5. The method according to claim 4, wherein vacuum is supplied through a fluid conduit in fluid communication with the vacuum source and the port.
  • 6. The method according to claim 1, further comprising delivering energy to the three-dimensional film material with an energy source and a transmitter.
  • 7. The method according to claim 6, wherein the transmitter comprises an ultrasonic horn.
CROSS REFERENCE TO RELATED APPLICATION

This application is a continuation of U.S. application Ser. No. 15/087,909, filed Mar. 31, 2016, which is a continuation application of U.S. application Ser. No. 12/489,883, filed on Jun. 23, 2009, which claims priority to, and the benefit of, U.S. Provisional Application Ser. No. 61/094,517, filed on Sep. 5, 2008 by Heagle, the entire contents of which are being incorporated by reference herein.

US Referenced Citations (316)
Number Name Date Kind
3367332 Groves Feb 1968 A
3486504 Austin, Jr. Dec 1969 A
3572340 Lloyd et al. Mar 1971 A
3712298 Snowdon et al. Jan 1973 A
3809086 Schachet et al. May 1974 A
3874387 Barbieri Apr 1975 A
3929135 Thompson Dec 1975 A
3972328 Chen Aug 1976 A
4029598 Neisius et al. Jun 1977 A
4080970 Miller Mar 1978 A
4112947 Nehring Sep 1978 A
4112949 Rosenthal et al. Sep 1978 A
4136696 Nehring Jan 1979 A
4266545 Moss May 1981 A
4382441 Svedman May 1983 A
4508256 Radel et al. Apr 1985 A
4524064 Nambu Jun 1985 A
4710165 McNeil et al. Dec 1987 A
4728499 Fehder Mar 1988 A
4743232 Kruger May 1988 A
4813942 Alvarez Mar 1989 A
4969880 Zamierowski Nov 1990 A
4990137 Graham Feb 1991 A
4997438 Nipper Mar 1991 A
5056510 Gilman Oct 1991 A
5071409 Rosenberg Dec 1991 A
5100395 Rosenberg Mar 1992 A
5100396 Zamierowski Mar 1992 A
5106629 Cartmell et al. Apr 1992 A
5141503 Sewell, Jr. Aug 1992 A
5149331 Ferdman et al. Sep 1992 A
5152757 Eriksson Oct 1992 A
5160322 Scheremet et al. Nov 1992 A
5176663 Svedman et al. Jan 1993 A
5178157 Fanlo Jan 1993 A
5181905 Flam Jan 1993 A
5195977 Pollitt Mar 1993 A
5238732 Krishnan Aug 1993 A
5261893 Zamierowski Nov 1993 A
5263922 Sova et al. Nov 1993 A
D364679 Heaton et al. Nov 1995 S
5484427 Gibbons Jan 1996 A
5527293 Zamierowski Jun 1996 A
5536233 Khouri Jul 1996 A
5549584 Gross Aug 1996 A
5588958 Cunningham et al. Dec 1996 A
5636643 Argenta et al. Jun 1997 A
5645081 Argenta et al. Jul 1997 A
5678564 Lawrence et al. Oct 1997 A
5701917 Khouri Dec 1997 A
5707499 Joshi et al. Jan 1998 A
5733305 Fleischmann Mar 1998 A
5759570 Arnold Jun 1998 A
5779657 Daneshvar Jul 1998 A
5840049 Tumey et al. Nov 1998 A
5852126 Barnard et al. Dec 1998 A
5911222 Lawrence et al. Jun 1999 A
5944703 Dixon et al. Aug 1999 A
6010524 Fleischmann Jan 2000 A
6071267 Zamierowski Jun 2000 A
6117111 Fleischmann Sep 2000 A
6135116 Vogel et al. Oct 2000 A
D434150 Turney et al. Nov 2000 S
6142982 Hunt et al. Nov 2000 A
6174306 Fleischmann Jan 2001 B1
6203563 Fernandez Mar 2001 B1
6261276 Reitsma Jul 2001 B1
6325788 McKay Dec 2001 B1
6345623 Heaton et al. Feb 2002 B1
6348423 Griffiths et al. Feb 2002 B1
6398767 Fleischmann Jun 2002 B1
6406447 Thrash et al. Jun 2002 B1
6420622 Johnston et al. Jul 2002 B1
6458109 Henley et al. Oct 2002 B1
6488643 Tumey et al. Dec 2002 B1
6500112 Khouri Dec 2002 B1
D469175 Hall et al. Jan 2003 S
D469176 Hall et al. Jan 2003 S
6520982 Boynton et al. Feb 2003 B1
6553998 Heaton et al. Apr 2003 B2
D475134 Randolph May 2003 S
6557704 Randolph May 2003 B1
D478659 Hall et al. Aug 2003 S
6607495 Skalak et al. Aug 2003 B1
6626891 Ohmstede Sep 2003 B2
6648862 Watson Nov 2003 B2
6685681 Lockwood et al. Feb 2004 B2
6689986 Patel et al. Feb 2004 B2
6695823 Lina et al. Feb 2004 B1
6695824 Howard et al. Feb 2004 B2
D488558 Hall Apr 2004 S
6752794 Lockwood et al. Jun 2004 B2
6755807 Risk, Jr. et al. Jun 2004 B2
6764462 Risk, Jr. et al. Jul 2004 B2
6767334 Randolph Jul 2004 B1
6800074 Henley et al. Oct 2004 B2
6814079 Heaton et al. Nov 2004 B2
6824533 Risk, Jr. et al. Nov 2004 B2
6855135 Lockwood et al. Feb 2005 B2
6855860 Ruszczak et al. Feb 2005 B2
6856821 Johnson Feb 2005 B2
6887228 McKay May 2005 B2
6887263 Bleam et al. May 2005 B2
6936037 Bubb et al. Aug 2005 B2
6942633 Odland Sep 2005 B2
6942634 Odland Sep 2005 B2
6951553 Bubb et al. Oct 2005 B2
6960181 Stevens Nov 2005 B2
6979324 Bybordi et al. Dec 2005 B2
6994702 Johnson Feb 2006 B1
7004915 Boynton et al. Feb 2006 B2
7022113 Lockwood et al. Apr 2006 B2
7037254 O'Connor et al. May 2006 B2
7052167 Vanderschuit May 2006 B2
7070584 Johnson et al. Jul 2006 B2
7077832 Fleischmann Jul 2006 B2
7108683 Zamierowski Sep 2006 B2
7117869 Heaton et al. Oct 2006 B2
7128719 Rosenberg Oct 2006 B2
7128735 Weston Oct 2006 B2
7144390 Hanningan et al. Dec 2006 B1
7169151 Lytinas Jan 2007 B1
7182758 McCraw Feb 2007 B2
7195624 Lockwood et al. Mar 2007 B2
7198046 Argenta et al. Apr 2007 B1
7214202 Vogel et al. May 2007 B1
7216651 Argenta et al. May 2007 B2
D544092 Lewis Jun 2007 S
7273054 Heaton et al. Sep 2007 B2
7276051 Henley et al. Oct 2007 B1
7279612 Heaton et al. Oct 2007 B1
7316672 Hunt et al. Jan 2008 B1
D565177 Locke et al. Mar 2008 S
7338482 Lockwood et al. Mar 2008 B2
7351250 Zamierowski Apr 2008 B2
7361184 Joshi Apr 2008 B2
7381211 Zamierowski Jun 2008 B2
7381859 Hunt et al. Jun 2008 B2
7381860 Gudnason et al. Jun 2008 B2
7396345 Knighton et al. Jul 2008 B2
7410495 Zamierowski Aug 2008 B2
7413570 Zamierowski Aug 2008 B2
7413571 Zamierowski Aug 2008 B2
7422576 Boynton et al. Sep 2008 B2
7494482 Orgill et al. Feb 2009 B2
7534927 Lockwood et al. May 2009 B2
7569742 Haggstrom et al. Aug 2009 B2
7605298 Bechert et al. Oct 2009 B2
7612247 Oyaski Nov 2009 B2
7615036 Joshi et al. Nov 2009 B2
7622629 Aail Nov 2009 B2
7625362 Boehringer et al. Dec 2009 B2
7670323 Hunt et al. Mar 2010 B2
7699823 Haggstrom et al. Apr 2010 B2
7700819 Ambrosio et al. Apr 2010 B2
7708724 Weston May 2010 B2
7722582 Lina et al. May 2010 B2
7723560 Lockwood et al. May 2010 B2
7731702 Bybordi et al. Jun 2010 B2
7749531 Booher Jul 2010 B2
7759537 Bishop et al. Jul 2010 B2
7759539 Shaw et al. Jul 2010 B2
7775998 Riesinger Aug 2010 B2
7776028 Miller et al. Aug 2010 B2
7779625 Joshi et al. Aug 2010 B2
7811269 Boynton et al. Oct 2010 B2
7838717 Haggstrom et al. Nov 2010 B2
7846141 Weston Dec 2010 B2
7896856 Petrosenko et al. Mar 2011 B2
7909805 Weston Mar 2011 B2
7910791 Coffey Mar 2011 B2
7922703 Riesinger Apr 2011 B2
7927318 Risk, Jr. et al. Apr 2011 B2
7959624 Riesinger Jun 2011 B2
7964766 Blott et al. Jun 2011 B2
7976519 Bubb et al. Jul 2011 B2
8007257 Heaton et al. Aug 2011 B2
8034037 Adams et al. Oct 2011 B2
8062272 Weston Nov 2011 B2
8062331 Zamierowski Nov 2011 B2
8080702 Blott et al. Dec 2011 B2
8118794 Weston Feb 2012 B2
8152785 Vitaris Apr 2012 B2
8162907 Heagle Apr 2012 B2
8168848 Lockwood et al. May 2012 B2
8207392 Haggstrom et al. Jun 2012 B2
8235972 Adahan Aug 2012 B2
8241261 Randolph et al. Aug 2012 B2
8282611 Weston Oct 2012 B2
8303552 Weston Nov 2012 B2
8372049 Jaeb et al. Feb 2013 B2
8372050 Jaeb et al. Feb 2013 B2
8425478 Olson Apr 2013 B2
8444612 Patel et al. May 2013 B2
8460255 Joshi et al. Jun 2013 B2
8513481 Gergeley et al. Aug 2013 B2
8535283 Heaton et al. Sep 2013 B2
8545466 Andresen et al. Oct 2013 B2
8556871 Mormino et al. Oct 2013 B2
8568386 Malhi Oct 2013 B2
8628505 Weston Jan 2014 B2
8641691 Fink et al. Feb 2014 B2
8663198 Buan et al. Mar 2014 B2
8679079 Heaton et al. Mar 2014 B2
8715256 Greener May 2014 B2
8764732 Hartwell Jul 2014 B2
8795243 Weston Aug 2014 B2
8808274 Hartwell Aug 2014 B2
8829263 Haggstrom et al. Sep 2014 B2
8834451 Blott et al. Sep 2014 B2
8834452 Hudspeth et al. Sep 2014 B2
8864748 Coulthard et al. Oct 2014 B2
8956336 Haggstrom et al. Feb 2015 B2
9012714 Fleischmann Apr 2015 B2
9168330 Joshi et al. Oct 2015 B2
9199012 Vitaris et al. Dec 2015 B2
9220822 Hartwell Dec 2015 B2
9302033 Riesinger Apr 2016 B2
9375353 Vitaris et al. Jun 2016 B2
9375521 Hudspeth et al. Jun 2016 B2
9381283 Adams et al. Jul 2016 B2
9414968 Heagle Aug 2016 B2
9421309 Robinson et al. Aug 2016 B2
9446178 Blott et al. Sep 2016 B2
9452248 Blott et al. Sep 2016 B2
9629986 Patel et al. Apr 2017 B2
9669138 Joshi et al. Jun 2017 B2
9795725 Joshi et al. Oct 2017 B2
9844473 Blott et al. Dec 2017 B2
9956121 Hartwell May 2018 B2
9962474 Greener May 2018 B2
10016309 Hartwell Jul 2018 B2
20010031943 Urie Oct 2001 A1
20010043943 Coffey Nov 2001 A1
20020016577 Ohmstede Feb 2002 A1
20020143286 Tumey Oct 2002 A1
20020151836 Burden Oct 2002 A1
20020161346 Lockwood et al. Oct 2002 A1
20030078532 Ruszczak et al. Apr 2003 A1
20030093041 Risk, Jr. et al. May 2003 A1
20030212357 Pace Nov 2003 A1
20030212359 Butler Nov 2003 A1
20030219469 Johnson et al. Nov 2003 A1
20040039415 Zamierowski Feb 2004 A1
20040057855 Gerlach et al. Mar 2004 A1
20040064111 Lockwood et al. Apr 2004 A1
20040064132 Boehringer et al. Apr 2004 A1
20040093026 Weidenhagen et al. May 2004 A1
20040122434 Argenta et al. Jun 2004 A1
20040167482 Watson Aug 2004 A1
20040193218 Butler Sep 2004 A1
20040241213 Bray Dec 2004 A1
20040249353 Risk, Jr. et al. Dec 2004 A1
20040260230 Randolph Dec 2004 A1
20050020955 Sanders et al. Jan 2005 A1
20050085795 Lockwood et al. Apr 2005 A1
20050090787 Risk, Jr. et al. Apr 2005 A1
20050131327 Lockwood et al. Jun 2005 A1
20050137539 Biggie et al. Jun 2005 A1
20050147562 Hunter et al. Jul 2005 A1
20050177190 Zamierowski Aug 2005 A1
20050182445 Zamierowski Aug 2005 A1
20060009744 Erdman et al. Jan 2006 A1
20060029650 Coffey Feb 2006 A1
20060039742 Cable, Jr. et al. Feb 2006 A1
20060100586 Karpowicz et al. May 2006 A1
20060149170 Boynton et al. Jul 2006 A1
20070005028 Risk, Jr. et al. Jan 2007 A1
20070014837 Johnson et al. Jan 2007 A1
20070016152 Karpowicz Jan 2007 A1
20070021697 Ginther et al. Jan 2007 A1
20070027414 Hoffman et al. Feb 2007 A1
20070032754 Walsh Feb 2007 A1
20070032755 Walsh Feb 2007 A1
20070032778 Heaton et al. Feb 2007 A1
20070040454 Freudenberger et al. Feb 2007 A1
20070055209 Patel et al. Mar 2007 A1
20070066925 Gudnason et al. Mar 2007 A1
20070178145 Chou et al. Aug 2007 A1
20070179460 Adahan Aug 2007 A1
20070225663 Watt et al. Sep 2007 A1
20070299369 Babaev Dec 2007 A1
20080031748 Ihle et al. Feb 2008 A1
20080071235 Locke et al. Mar 2008 A1
20080132821 Propp et al. Jun 2008 A1
20080200857 Lawhorn Aug 2008 A1
20080200905 Heaton et al. Aug 2008 A1
20080200906 Sanders et al. Aug 2008 A1
20080208147 Argenta et al. Aug 2008 A1
20080234641 Locke et al. Sep 2008 A1
20080306456 Riesinger Dec 2008 A1
20090125004 Shen et al. May 2009 A1
20090157024 Song Jun 2009 A1
20090234306 Vitaris Sep 2009 A1
20090275922 Coulthard et al. Nov 2009 A1
20090299251 Buan Dec 2009 A1
20090299306 Buan Dec 2009 A1
20100125258 Coulthard et al. May 2010 A1
20100259406 Caso et al. Oct 2010 A1
20100318052 Ha et al. Dec 2010 A1
20110118683 Weston May 2011 A1
20110295220 Heaton et al. Dec 2011 A1
20130090615 Jaeb et al. Apr 2013 A1
20130102979 Coulthard et al. Apr 2013 A1
20130138054 Fleischmann May 2013 A1
20130150814 Buan Jun 2013 A1
20130165878 Heagle Jun 2013 A1
20130274688 Weston Oct 2013 A1
20130338614 Heaton et al. Dec 2013 A1
20140155849 Heaton et al. Jun 2014 A1
20150065965 Haggstrom Mar 2015 A1
20160256673 Heagle Sep 2016 A1
20160317357 Vitaris et al. Nov 2016 A1
20170128642 Buan May 2017 A1
20170181896 Hartwell Jun 2017 A1
20170181897 Hartwell Jun 2017 A1
Foreign Referenced Citations (61)
Number Date Country
34 43 101 May 1986 DE
41 11 122 Apr 1993 DE
295 04 378 Oct 1995 DE
20 2004 017 052 Jun 2005 DE
0 020 662 Jul 1984 EP
0 340 018 Nov 1989 EP
0 358 302 Mar 1990 EP
0 853 950 Jul 1998 EP
1 088 569 Apr 2001 EP
1 219 311 Jul 2002 EP
1 476 217 Nov 2004 EP
1 955 887 Aug 2008 EP
2 079 507 Jul 2009 EP
2 462 908 Jun 2012 EP
2 687 245 Jan 2014 EP
2 711 034 Mar 2014 EP
2 305 325 Apr 2014 EP
2 345 437 Apr 2014 EP
1 163 907 Oct 1958 FR
1255395 Dec 1971 GB
1 549 756 Aug 1979 GB
2 195 255 Apr 1988 GB
2 235 877 Mar 1991 GB
2 307 180 Nov 1996 GB
2 329 127 Mar 1999 GB
2 336 546 Oct 1999 GB
2 344 531 Jun 2000 GB
2 415 908 Jan 2006 GB
1762940 Jan 1989 SU
WO 198001139 Jun 1980 WO
WO 198002182 Oct 1980 WO
WO 198300742 Mar 1983 WO
WO 198401904 May 1984 WO
WO 198905133 Jun 1989 WO
WO 199011795 Oct 1990 WO
WO 199219313 Nov 1992 WO
WO 1993009727 May 1993 WO
WO 199420041 Sep 1994 WO
WO 199605873 Feb 1996 WO
WO 200021586 Apr 2000 WO
WO 2003005943 Jan 2003 WO
WO 2003018098 Mar 2003 WO
WO 2003030966 Apr 2003 WO
WO 2003045492 Jun 2003 WO
WO 2003057070 Jul 2003 WO
WO 2003057307 Jul 2003 WO
WO 2003086232 Oct 2003 WO
WO 2003092620 Nov 2003 WO
WO 2003101508 Dec 2003 WO
WO 2004018020 Mar 2004 WO
WO 2004077387 Sep 2004 WO
WO 2005009488 Feb 2005 WO
WO 2005025447 Mar 2005 WO
WO 2005123170 Dec 2005 WO
WO 2006052839 May 2006 WO
WO 2006105892 Oct 2006 WO
WO 2008039223 Apr 2008 WO
WO 2009066105 May 2009 WO
WO 2009124100 Oct 2009 WO
WO 2009158128 Dec 2009 WO
WO 2010142959 Dec 2010 WO
Non-Patent Literature Citations (56)
Entry
US 6,216,701 B1, 04/2001, Heaton et al. (withdrawn)
US 7,186,244 B1, 03/2007, Hunt et al. (withdrawn)
International Search Report, re PCT Application No. PCT/US09/48351, dated Oct. 28, 2009.
Aubrey, D.A., et al., Treatment of the Perineal Wound after Proctectomy by Intermittent Irrigation, Arch. Surg., Oct. 1984, 119, 1141-1144.
Bagautdinov, N.A., “Variant of External Vacuum Aspiration in the Treatment of Purulent Diseases of Soft Tissues,” in current Problems in Modern Clinical Surgery: Interdepartmental Collection, edited by V. Ye. Volkov et al. (Chuvashia State University, Cheboksary, USSR 1986) pp. 94-96 (with English translation).
Arnljots, et al., “Irrigation Treatment in Split-thickness Skin Grafting of Intractable Leg Ulcers,” Scand J Plast Reconstr Surg 19: 211-213,1985.
Chardack, et al., “Experimental studies on Synthetic Substitutes for Skin and Their Use in the Treatment of Burns,” vol. 155, No. 1 (128-136), 1961.
Chariker, M.E., et al, “Effective Management of Incisional and Cutaneous Fistulae with Closed Suction Wound Drainage,” Contemporary Surgery. Jun. 1989, pp. 59-63, vol. 34.
Fleischmann, “Vacuum Sealing for Treatment of Problematical Wounds”, University Surgical Clinic and Polyclinic—Accident Surgery Department, WundForum Spezial-IHW 94.
Fleischmann et al., “Vacuum Sealing: Indication, Technique and Results”, Emr J Orthop Surg Tramatol (1995) 5:37-40.
Garcia-Rinaldi, R., et al., Improving the Efficiency of Wound Drainage Catheters, Amer. Journ. of Surg., Sep. 1975, 130, 372-373.
Gorica Zivadinovic, et al., “Vacuum Therapy in the Treatment of Peripheral Blood Vessels,” Conference Papers of the 5th Timok Medical Days, Majdanpek, 1986 (161-164).
Health Technology, Literature R., “Vacuum Assisted Closure Therapy for Wound Care”, Health Technology Literature Review (Dec. 2004), 3-59.
Jeter, Katherine F., et al., “Managing Draining Wounds and Fistulae: New and Established Methods”, Chronic Wound Care, 1990, pp. 240-246.
Kostiuchenok, B. M., et al., “The Vacuum Effect in the Surgical Treatment of Purulent Wounds”, The Kremlin Papers: Perspectives in Wound Care, Russian Journal: Vestnik Khirurgii, BlueSky Publishing, La Costa, California (2004), 3-4.
Kostiuchenok, et al., “The Vacuum Effect in the Surgical Treatment of Purulent Wounds,” Russian Journal: Vestnik Khirurgii, Sep. 1986 (18-21).
Meyer, MD., et al., “In Surgery, Medicine and the Specialties a Manual of its Practical Application”, Bier's Hyperemic Treatment, Second Revised Edition, W.B. Saunders Company, 1909.
Morykwas, Michael J., et al., “Vacuum-Assisted Closure: A New Method for Wound Control and Treatment: Animal Studies and Basic Foundation”, Ann Plast Surg 1997;38:553-562 (Dec. 10, 1996).
Mulder, GD, et al., “Clinicians' Pocket Guide to Chronic Wound Repair,” Wound Healing Publications Second Edition, 1991.
Ryosuke Fujimoro, MD., et al., “Sponge Fixation Method for Treatment of Early Scars,” From the Department of Dermatology in the Faculty Medicine, Kyoto University, vol. 42, No. 4, Oct. 1968 (322-326).
Sandén, Göran MD., et al., “Staphylococcal Wound Infection in the Pig: Part II. Innoculation, Quantification of Bacteria, and Reproducibility,” Annals of Plastic Surgery, vol. 23, No. 3, Sep. 1989, (219-223).
Stewart, Joanne, Ph.D., World Wide Wounds—Next generation of products for wound management—2002 (13 pages).
Stoll, “Energetic Remedies—Cupping: Healing Within a Vacuum,” https:l/www.suite101.com/article.cfm/ energetic)remedies/74531, Apr. 13, 2005.
Svedman, “A Dressing Allowing Continuous Treatment of a Biosurface” IRCS Medical Science: Biomedical Technology; Clinical Medicine; Surgery and Transplantation, 7, 221 (1979).
Svedman, “A Dressing System Providing Fluid Supplu and Suction Drainage Used for Continuous or Intermittent Irrigation,” Annals of Plastic Surgery, vol. 17, No. 2, Aug. 1986 (125-133).
Svedman, P., “Irrigation Treatment of Leg Ulcers,” The Lancet, Sep. 3, 1983 (532-534).
Svedman, et al., “Staphylococcal Wound Infection in the Pig: Part I. Course,” Annals of Plastic Surgery, vol. 23, No. 3, Sep. 1989 (212-218).
Teder et al., “Continuous Wound Irrigation in the Pig,” Journal of Investigative Surgery, 1990, vol. 3, pp. 399-407.
Tribble, David E. M.D., An Improved Sump Drain-Irrigation Device of Simple Construction, Archives of Surgery New York, pp. 511-513, 1972 vol. 105.
Usupov, et al., “Archive Wound Drainage,” Russian Journal: Vestnik Khirugii, Apr. 1987 (42-45).
Wu, W.S., et al., Vacuum therapy as an intermediate phase in wound closure: a clinical experience, Eur J. Past Surg (2000) 23: 174-177.
Yu A. Davydov, et al., “Bacteriological and Cytological Assessment of Vacuum Therapy of Purulent Wounds”, Vestnik Khirurgii, Oct. 1988 (48-52).
Yu A. Davydov, et al., “Concepts for Clinical Biological Management of the Wound Process in the Treatment of Purulent Wounds Using Vacuum Therapy,” Vestnik Khirugii, Feb. 1991, 132-135).
Yu A. Davydov, et al., “Vacuum Therapy in the Treatment of Purulent Lactation Mastitis,” Russian Journal: Vesnik Khirurgii, Sep. 1986 (66-70).
Yu A. Davydov, et al., “Vacuum Therapy in treatment of Acute Purulent Diseases of Soft Tissues and Purulent Wounds,” Vestnik Khirurgii, (Surgeon's Herald), Medicine Publishers, 1986.
International Search Report and Written Opinion, re PCT Application No. PCT/US2009/48351, dated Nov. 13, 2009.
International Preliminary Report, re PCT Application No. PCT/US2009/48351, dated Mar. 17, 2011.
“Technology Watch”, May 1989, in 1 page.
Aubrey, D.A., et al., Treatment of the Perineal Wound after Proctectomy by Intermittent Irrigation, Arch. Surg., Oct. 1984, 119, 1141-1144, in 4 pages.
Bier, A., Hyperemia as a Therapeutic Agent, Ed. Dr. Gustavus M. Blech, A. Robertson & Co., Chicago 1905.
Bucalo et al. “Inhibition of Cell Proliferation by Chronic Wound Fluid.” Wound Repair and Regeneration. Miami, 1993. pp. 181-186.
Edlich, R.F., et al., “Evaluation of a New, Improved Surgical Drainage System,” The American Journal of Surgery, vol. 149, pp. 295-298, Feb. 1985.
Garcia-Rinaldi, R., et al., Improving the Efficiency of Wound Drainage Catheters, Amer. Journ. of Surg., Sep. 1975, 130, 372-373, in 2 pages.
Health Technology Literature Review, “Vacuum Assisted Closure Therapy for Wound Care”, The Medical Advisory Secretariat, Dec. 2004, pp. 3-57, in 57 pages.
Hersle, K. et al., “Uses of Dextranomer Absorbent Pads After Cryosurgery of Cutaneous Malignancies”, The Journal of Dermatologic Surgery and Oncology, vol. 8, Jan. 1982, in 4 pages.
Kendall ULTEC Hydrocolloid Dressing (4″×4″), product ordering page, web page downloaded Jul. 13, 2014, in 1 page.
McLaughlan, James, Sterile Microenvironment for Postoperative Wound Care, The Lancet, pp. 503-504, Sep. 2, 1978.
Advantec MFS, Inc., “Membrane Filters” (catalog), accessed Jan. 29, 2016 (publication date unknown, but believed to be copyright 2001-2011), in 17 pages. URL: http://www.advantecmfs.com/catalog/filt/membrane.pdf#page=11.
Morykwas, Michael J., et al., “Vacuum-Assisted Closure: A New Method for Wound Control and Treatment: Animal Studies and Basic Foundation”, Ann Plast Surg 1997; 38:553-562 (Dec. 10, 1996), in 10 pages.
Protz, K., “Moderne Wundauflagen unterstutzen Heilungsprozess”, Wundversorgung: Indikation and Anwendung, Geriatrie Journal, Apr. 2005, pp. 3333-3339, with translation, in 17 pages.
Renasys EZ System for Negative Wound Therapy, Smith & Nephew announcement, dated Feb. 24, 2009, in 3 pages.
Sames, C.P., Sealing of Wounds with Vacuum Drainage, Br. Med. Journ., Nov. 5, 1977, p. 1223, Correspondence.
Smith & Nephew, “PICO Single Use Negative Pressure Wound Therapy System”, spiral booklet, Mar. 2011, in 7 pages.
Stewart, Joanne, Ph.D., World Wide Wounds—Next generation of products for wound management—2002, in 13 pages.
Tribble, D. M.D., “An Improved Sump Drain-Irrigation Device of Simple Construction”, Archives of Surgery New York, pp. 511-513, 1972 vol. 105, in 4 pages.
Wu, W.S., et al. Vacuum therapy as an intermediate phase in wound closure: a clinical experience, Eur J Past Surg (2000) 23: 174-177, in 6 pages.
Related Publications (1)
Number Date Country
20170252545 A1 Sep 2017 US
Provisional Applications (1)
Number Date Country
61094517 Sep 2008 US
Continuations (2)
Number Date Country
Parent 15087909 Mar 2016 US
Child 15436469 US
Parent 12489883 Jun 2009 US
Child 15087909 US